Kenji Yasukawa (Astellas)
Astellas snaps up mitochondria-focused biotech, beefs up drug discovery in budget deal
Astellas has shown it can go big when it sees something it wants for the sprawling R&D organization it’s building, wagering $3 billion on gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
